Abbott's second-quarter results are in, and we delivered another strong quarter in healthcare sector growth thanks to a strong product pipeline and outstanding execution by our management team.

For the quarter, Abbott beat Street estimates on the top and bottom line, delivering impressive organic sales and double-digit EPS growth. Today's results extend our decade-long streak of meeting or beating Street-adjusted EPS estimates every quarter.

And, with all four of our businesses — Diagnostics, Devices, Nutrition and Medicines — contributing to strong growth in the quarter, Abbott announced plans to raise its outlook for the rest of the year.

The strong healthcare sector growth we're achieving is a direct result of the strategic steps we've taken to position the company in the most attractive areas of healthcare and the productivity of our life-changing technologies.

What follows is just a few of our highlights from the quarter:

• XIENCE Sierra^™, the newest generation of our gold-standard coronary stent system, was approved in the U.S. and received national reimbursement in Japan.
• Advisor^™ HD Grid Mapping Catheter, Sensor Enabled, which includes a first-of-its-kind configuration to create highly detailed maps of the heart to help physicians perform cardiac ablation procedures, was approved in the U.S.
• FreeStyle Libre™, our revolutionary continuous glucose monitor, continues to have unparalleled uptake. New real-world evidence from more than 250,000 FreeStyle Libre users showed that increased scanning is associated with improved glucose control.
• Ensure^® Max Protein was launched in the U.S., helping people refuel their bodies with 30 grams of high-quality protein and 1 gram of sugar.

For full financials, you can read our press release, but major highlights are included in the materials below:

Abbott's Chairman and CEO Miles D. White shared his views on second-quarter performance: